Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 65 от 154

Набира участници Фаза 3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Primary Generalized Tonic-Clonic Seizures

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Начало: 14.02.2023 Край: 01.06.2027 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +15 Xenon Pharmaceuticals Inc. NCT05667142

Набира участници Фаза 1

Autologous Tumour Vaccine Trial

Solid Tumor

Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents

Начало: 10.02.2023 Край: 10.02.2028 Лечение

Australia Vaxine Pty Ltd NCT05807035

Набира участници Фаза 4

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Surgical Site Infection

This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery

Начало: 07.02.2023 Край: 01.06.2028 Възраст: от 18 г. Превенция

Australia, Canada, Malaysia +2 Monash University NCT05447559

Набира участници Фаза 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Metastatic Renal Cell Carcinoma Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Unresectable Renal Cell Carcinoma

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Начало: 01.02.2023 Край: 15.06.2028 Възраст: от 18 г. Лечение

Australia, Canada, Ireland +1 NRG Oncology NCT05327686

Набира участници

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

The goal of this observational study is to learn if offering a point-of-care screening test for exposure to the Hepatitis C virus, before providing a diagnostic test for Hepatitis C infection can increase testing, diagnosis and treatment in Adults. Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of Hepatitis C viral infection. The main question it aims to answer is: What proportion of the participants that have been diagnosed with HCV infection have started treatment when their records are reviewed 12 weeks after diagnosis? Participants will have one in-person visit where they will provide informed consent and receive a finger-prick rapid result test for Hepatitis C infection. Participants with no previous Hepatitis C infection will have a screening test to see if they have an immune reaction to Hepatitis C. Participants who know they have been infected with Hepatitis C in the past, and all participants with a positive screening test result will then be given a Hepatitis C diagnostic test at this visit. No treatment is provided as a part of this study, participants who are diagnosed with Hepatitis C infection will be referred to testing locations standard of care for any additional clinical assessments and treatment initiation. A review of the participant's records will be made 12 weeks after their Hepatitis C result and their treatment data are gathered.

Начало: 25.01.2023 Край: 01.01.2027 Възраст: от 18 г.

Australia Kirby Institute NCT05713136

Набира участници Фаза 1/2

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

HIV I Infection

The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This is the reason why people living with HIV are unable to stop their antiretroviral treatment.

Начало: 24.01.2023 Край: 01.01.2029 Възраст: 18–65 г. Лечение

Australia, Singapore University of Melbourne NCT05187429

Набира участници Фаза 1/2

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Breast Cancer Metastatic Breast Cancer

This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.

Начало: 24.01.2023 Край: 28.12.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +14 Stemline Therapeutics, Inc. NCT05563220

Набира участници Фаза 2

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.

Начало: 23.01.2023 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia Australasian Gastro-Intestinal Trials Group NCT05694936

Набира участници Фаза 3

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

H3 K27M Glioma

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

Начало: 23.01.2023 Край: 01.06.2028 Лечение

Argentina, Australia, Brazil +13 Jazz Pharmaceuticals NCT05580562

Набира участници Фаза 1

Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1/2 dual inhibitor, in solid tumors. The study is comprised of Dose-Escalation Part followed by randomized Dose-Ranging Part and Dose-Expansion Part. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish the MTD or RD for randomized Dose-Ranging Part. Dose-Ranging Part is designed mainly to further evaluate safety and preliminary efficacy of HM97662 monotherapy in subjects with specific genomic alterations to more precisely determine the potential RP2D that are to be tested in a Dose-Expansion Part. Dose-Expansion Part is designed to assess the potential efficacy of HM97662 monotherapy when administered at the RP2D to subjects in indication-specific expansion cohorts.

Начало: 11.01.2023 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, South Korea Hanmi Pharmaceutical Company Limited NCT05598151

Набира участници Фаза 3

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Type 2 Diabetes

The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.

Начало: 01.01.2023 Край: 30.06.2026 Възраст: от 18 г. Превенция

Australia, Sri Lanka The George Institute NCT05345327

Набира участници

SSVEP Evaluation of Brain Function (PRO)

Mild Traumatic Brain Injury

The investigational device used in this clinical investigation, the Nurochek PRO System (NCPRO), is a portable electroencephalogram (EEG) headset which delivers a visual stimulus and measures a VEP. The visual stimulus is delivered to the subjects' eyes via light-emitting diodes, and the EEG measures the user's visual-evoked potential. This headset communicates with an application on a computer, which processes the signals and transmits them to a secure cloud server for analysis and storage of the data. Nurochek PRO is a development of the previously FDA cleared Nurochek System. The primary objective of this clinical investigation was to evaluate the performance of the investigational device (NCPRO) against clinical diagnosis of detection of mild traumatic brain injury (mTBI). The primary endpoint outlined for this study was set at the collection of 100 valid investigational device readings from individuals with concussion and 500 valid investigational device readings from healthy individuals who have had a plausible mechanism of sustaining a concussion, but do not have one. Additionally, readings from healthy individuals are also to be acquired. The aim of this study was to collect data from 100 readings from individuals with concussion. The initial assumption was that sites would provide players pre-season and make players available for testing post-concussion. In practice, some sites provided player data only post-concussion event (such as medical clinics). Participants were acquired from sporting clubs, medical clinicals and schools.

Начало: 01.01.2023 Край: 01.01.2026 Възраст: от 12 г.

Australia Headsafe MFG NCT06013566

Набира участници Фаза 3

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.

Начало: 29.12.2022 Край: 24.09.2027 Възраст: 40–80 г. Лечение

Argentina, Australia, Belgium +32 Hoffmann-La Roche NCT05595642

Набира участници Фаза 3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Hemophilia A Hemophilia B

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.

Начало: 28.12.2022 Край: 25.02.2040 Възраст: от 18 г. Друго

Australia, Taiwan, Turkey (Türkiye) +1 Pfizer NCT05568719

Набира участници

Metastatic Leiomyosarcoma Biomarker Protocol

Leiomyosarcoma

Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.

Начало: 22.12.2022 Край: 01.12.2026

Australia, United States University of Michigan Rogel Cancer Center NCT05653388

Набира участници Фаза 1

First in Human Study of AZD9592 in Solid Tumors

Advanced Solid Tumours Carcinoma Non-small Cell Lung Head and Neck Neoplasms Colorectal Neoplasms

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.

Начало: 21.12.2022 Край: 06.10.2027 Възраст: от 18 г. Лечение

Australia, Canada, China +8 AstraZeneca NCT05647122

Набира участници Фаза 1/2

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Advanced Solid Tumor

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

Начало: 21.12.2022 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia, South Korea, United States Selecxine NCT05525247

Набира участници Фаза 3

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Diabete Type 2 Cardiovascular Diseases

To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.

Начало: 21.12.2022 Край: 01.12.2027 Възраст: 55–80 г. Превенция

Australia, Canada, Denmark +5 Montreal Heart Institute NCT05633810

Набира участници

European Myeloma Network (EMN) Sample Project

Multiple Myeloma Smoldering Multiple Myeloma Plasma Cell Leukemia Extramedullary Myeloma +1

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples. This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

Начало: 21.12.2022 Край: 01.12.2037 Възраст: от 18 г.

Australia, Belgium, Czechia +6 European Myeloma Network B.V. NCT06237803

Набира участници Фаза 1/2

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Gaucher Disease Gaucher Disease, Type 1

Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients. Following this, up to 6 patients may be enrolled in an expansion cohort. For each enrolled patient, the study will be approximately 5 years in duration, including up to a 60-day screening period. During the first 18 months after dosing, subjects will be evaluated for the effects of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will be followed for an additional 42 months to monitor safety, immunogenicity, and selected biomarker and efficacy parameters.

Начало: 20.12.2022 Край: 30.11.2031 Възраст: от 18 г. Лечение

Australia, Brazil, Germany +3 Prevail Therapeutics NCT05487599

1 … 63 64 65 66 67 … 154